NCT03065192 - Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 11, 2017

Primary Completion Date

August 10, 2021

Study Completion Date

August 10, 2021

Conditions

Idiopathic Parkinson's DiseaseParkinson's DiseaseBasal Ganglia DiseaseBrain DiseasesCentral Nervous System DiseasesMovement DisordersNervous System DiseasesNeurodegenerative DiseasesParkinsonian Disorders

Interventions

DRUG

VY-AADC01

Single dose, neurosurgically infused, bilaterally into the striatum.

Trial Locations (4)

15213

University of Pittsburgh Medical Center (UPMC), Pittsburgh

30322

Emory University, Atlanta

43210

Ohio State University (OSU), Columbus

94143

University of California, San Francisco (UCSF), San Francisco